leisure time -WSS

leisure time

author：explore 2025-09-30 23:40:50 - browse：726

When Prozac first entered the psychiatry scene in in the late ’80s, the profession was still Freud’s territory. Many considered taking medication to treat depression a failure. But that was all about to change, as early stewards like psychiatrist Peter Kramer refused to shy away from the new drug’s potential. These days, he says that people take for granted all of the progress that’s been made with antidepressant treatment in the past three decades.

“If you were going to be depressed any time in history and were interested in having an effective treatment, you would want to be alive now. But we’ve lost our wonderment about that,” said Kramer, the author of the groundbreaking 1993 book “Listening to Prozac.”

This week, Kramer joins me to discuss how the country’s relationship with antidepressants has changed since the publication of his book three decades ago. The conversation is based on his First Opinion, “What antidepressants are saying 30 years after the publication of ‘Listening to Prozac.’”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： How to save PrEP access — and even expand it
Next article： International team creates first chimeric human

WSS

Steward Health Care Massachusetts hospitals face fiscal disaster

Medical device lobby: We're tired of waiting on Medicare coverage

ALS groups 'won't be played again' by the FDA, drug sponsors

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Scientists unlock the key to scar

leisure time

leisure time

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Why depression after traumatic brain injury is distinct

Walensky prepares to leave CDC — and Congress — behind

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Heart attack and stroke risk calculators need revising

A Q&A with Aletha Maybank, AMA’s chief health equity officer

New air purifier tech could be key to improving indoor air quality

Why scientists need input from humanists on sensitive research

Medical records are filled with copy

House looks to weaken Medicare negotiation

knowledge

UCLA team creates talking throat patch for voice disorders

An inside look at PIPEs, biotech's buzzy new financing tool

ALS groups 'won't be played again' by the FDA, drug sponsors

HHS secretary Becerra pressed on Change HealthCare cyberattack

First U.S. drug developed to treat liver disease MASH is approved

Change Healthcare cyberattack outage could last weeks

hotspot

hotspot

focus

hotspot